New China Life Insurance (SEHK:1336) presented its 2025 annual results on March 30, 2026, showcasing record-breaking performance across core financial metrics while simultaneously revealing a significant fourth-quarter earnings shortfall. The presentation highlighted a transformative year for China's leading life insurer, though the company's Q4 earnings per share of $1.10 fell dramatically short of the $1.96 forecast, missing expectations by 43.88%. The stock declined 2.82% in after-hours trading to $45.46, reflecting investor disappointment despite the company's robust full-year achievements.
The mixed results underscore the complexity of China's insurance sector, where strong annual fundamentals can be offset by quarterly volatility driven by investment timing, regulatory changes, and macroeconomic pressures.
Annual Performance Highlights
New China Life's 2025 annual results demonstrated exceptional growth, with the company successfully concluding its "14th Five-Year Plan" with record highs across all major indicators. As detailed in the company's presentation, total assets reached RMB 1.9 trillion, representing a 12.2% year-over-year increase, while gross written premium climbed 14.9% to RMB 195.87 billion.
The standout metric was net profit attributable to shareholders, which surged 38.3% to RMB 36.28 billion, driven by superior investment performance and expanding margins. Return on equity reached an impressive 34.69%, up 8.81 percentage points year-over-year, positioning NCI among the most profitable insurers in the Chinese market. The company's embedded value grew 11.4% to RMB 287.84 billion, while shareholders received increased dividends of RMB 2.73 per share, up 7.9%.
The comprehensive strength metrics further illustrated the company's operational momentum, with operating revenue rising 19.0% to RMB 157.75 billion and equity attributable to shareholders increasing 15.9% to RMB 111.54 billion.
Detailed Financial Analysis
New China Life's value creation accelerated significantly in 2025, with new business value surging 57.4% to RMB 9.84 billion, reflecting improved product mix and pricing discipline. The NBV margin based on first-year premium reached 16.2%, up 1.5 percentage points, indicating enhanced profitability on new sales.
The business structure continued optimizing, with first-year regular premium representing 64.4% of first-year premium from long-term insurance business, demonstrating a shift toward more sustainable, recurring revenue streams. Renewal premiums accounted for 68.5% of gross written premium, reaching RMB 134.17 billion and providing stable cash flows.
Business quality metrics showed marked improvement, with the 13-month persistency ratio climbing to 97.1% and the 25-month persistency ratio jumping 7.1 percentage points to 93.3%. The surrender rate declined to just 1.5%, down 0.4 percentage points, indicating stronger customer retention and satisfaction.
Investment performance proved exceptional, with total investment income reaching RMB 104.33 billion, up 30.9% year-over-year. The total investment yield of 6.6% represented an 0.8 percentage point improvement, significantly outpacing the low interest rate environment affecting the broader insurance sector. This superior investment performance was the primary driver behind the company's profit surge.
Strategic Initiatives
New China Life initiated its "15th Five-Year Plan" in 2025, anchored to the vision of becoming "China's leading financial service group with insurance business at its core." The company adopted a strategic orientation of "embracing the big insurance philosophy and building a strong NCI," with three strategic mainlines: customer as the center; sales team as the foundation; employee as partner.
The insurer implemented a synergistic development model combining "insurance + service + investment," representing a comprehensive transformation from a traditional life insurance provider to an integrated financial services platform. This model aims to deepen customer relationships through expanded service offerings while leveraging investment expertise to enhance returns.
Product innovation delivered notable outcomes, with 95 new products launched during the year, bringing the total product portfolio to 211 offerings. The company built an innovative health insurance system integrating "product + service," including flagship products like "Pharma Assured" and "Healthcare Assured" that combine cash payment with medical and nursing services. The wealth management segment diversified with 26 commercial annuities, 15 of which were included in the individual pension list.
Channel Performance
The individual insurance channel achieved breakthrough performance, with first-year regular premium from long-term insurance business surging 43.8% to RMB 19.03 billion. New business value from this channel increased 19.4% to RMB 4.81 billion, while monthly average comprehensive productivity per capita jumped 43% to RMB 11,200, indicating significant efficiency gains.
The bancassurance channel realized comprehensive development, with gross written premium climbing 39.5% to RMB 72.10 billion. First-year premium from long-term insurance business increased 52.3% to RMB 37.93 billion, while new business value more than doubled, surging 110.2% to RMB 5.27 billion. This exceptional growth reflected strengthened bank partnerships and improved product positioning.
The service ecosystem matured significantly, with the radius covering over 4 million individual customers through five major service brands: XINHUA ZUN (quality life manager), XINHUA AN (guardian of home-based elderly care), XINHUA RUI (inclusive public welfare service provider), XINHUA YUE (travel-based healthcare and old-age care), and XINHUA KANG (full-cycle health partner). The company operates 53 healthcare and old-age care communities and 70 travel-based projects domestically and internationally.
Market Reaction and Outlook
Despite the impressive annual performance, New China Life's stock fell 2.82% in after-hours trading following the earnings release, reflecting investor disappointment with the Q4 earnings miss. The stock has delivered a 59.89% return over the past year but has declined 15.58% year-to-date, trading at $45.96 as of April 2, 2026, well below its 52-week high of $65.80.
The company's valuation metrics suggest potential value, with a P/E ratio of 5.17 and a PEG ratio of 0.12, indicating the stock trades at a low price relative to near-term earnings growth potential. The dividend yield of 6.35% provides attractive income for investors, with the company maintaining dividend payments for 12 consecutive years.
Looking ahead, analyst forecasts project EPS of $1.45 for 2026 and $1.36 for 2027, with revenue projections of $8.00 billion and $8.51 billion respectively. These estimates suggest more modest growth expectations following the exceptional 2025 performance.
Management emphasized continued focus on premium growth and investment performance while acknowledging challenges from the low interest rate environment, increased competition in the life insurance sector, and potential regulatory changes. The company plans to accelerate channel and team transformation, adopt modern marketing concepts centered on customer needs, and leverage its patient capital advantage to optimize asset allocation.
The core solvency margin ratio of 135.11%, up 11.04 percentage points, provides substantial financial flexibility to support growth initiatives and weather market volatility. As New China Life implements its 15th Five-Year Plan, the company's ability to balance rapid growth with profitability consistency will be critical to sustaining investor confidence and market valuation.